Price T Rowe Associates Inc. MD Sells 499,181 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Price T Rowe Associates Inc. MD lessened its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 11.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,966,956 shares of the company's stock after selling 499,181 shares during the period. Price T Rowe Associates Inc. MD owned approximately 3.18% of Vaxcyte worth $324,736,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. raised its position in shares of Vaxcyte by 4.6% in the fourth quarter. Vanguard Group Inc. now owns 11,961,687 shares of the company's stock worth $979,184,000 after buying an additional 521,204 shares in the last quarter. Capital Research Global Investors raised its holdings in shares of Vaxcyte by 26.8% in the 4th quarter. Capital Research Global Investors now owns 6,210,523 shares of the company's stock valued at $508,393,000 after acquiring an additional 1,312,302 shares in the last quarter. Franklin Resources Inc. boosted its position in shares of Vaxcyte by 3.0% during the 4th quarter. Franklin Resources Inc. now owns 2,869,332 shares of the company's stock valued at $234,884,000 after acquiring an additional 82,997 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Vaxcyte by 3.8% during the 4th quarter. Geode Capital Management LLC now owns 2,802,888 shares of the company's stock valued at $229,495,000 after acquiring an additional 102,106 shares during the last quarter. Finally, Alliancebernstein L.P. grew its holdings in shares of Vaxcyte by 8.1% during the fourth quarter. Alliancebernstein L.P. now owns 1,779,362 shares of the company's stock worth $145,659,000 after purchasing an additional 133,448 shares in the last quarter. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have issued reports on PCVX. The Goldman Sachs Group dropped their target price on shares of Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Cantor Fitzgerald initiated coverage on shares of Vaxcyte in a research report on Tuesday, April 22nd. They issued an "overweight" rating for the company. Needham & Company LLC restated a "buy" rating and set a $90.00 price target on shares of Vaxcyte in a research report on Tuesday, April 8th. Bank of America cut their price objective on Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Finally, Evercore ISI raised Vaxcyte to a "strong-buy" rating in a report on Monday, March 31st. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Vaxcyte presently has an average rating of "Buy" and a consensus target price of $136.50.

Vaxcyte Trading Up 5.7 %

Shares of PCVX stock traded up $1.87 during mid-day trading on Tuesday, reaching $34.77. The stock had a trading volume of 1,274,396 shares, compared to its average volume of 1,235,620. The stock's 50-day moving average price is $54.56 and its two-hundred day moving average price is $79.33. The firm has a market capitalization of $4.48 billion, a PE ratio of -7.56 and a beta of 1.26. Vaxcyte, Inc. has a 52-week low of $27.66 and a 52-week high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, beating analysts' consensus estimates of ($1.16) by $0.14. On average, equities research analysts forecast that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Insider Activity at Vaxcyte

In other Vaxcyte news, COO Jim Wassil sold 8,000 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $86.22, for a total value of $689,760.00. Following the completion of the transaction, the chief operating officer now owns 205,695 shares in the company, valued at approximately $17,735,022.90. This represents a 3.74 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 24,000 shares of company stock worth $1,946,720 over the last 90 days. 3.10% of the stock is owned by company insiders.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.